Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC

Stopped The study was withdrawn prior to participant enrollment due to administrative and protocol optimization considerations.

Conditions

• Head and Neck Cancer

Interventions

• DRUG: Tislelizumab
• DRUG: Afatinib
• RADIATION: Low dose radiotherapy

Sponsor

West China Hospital